Company Overview and News

32
CRISPR Science and Stocks: Knowing Enough to Invest

2018-06-20 zacks
By far the most exciting real-time revolution unfolding in Biotechnology is CRISPR gene editing. And the past few months have provided plenty of excitement for Biotech investors as the three public companies who are pure-play manifestations of the technology have made some dramatic moves -- on good news and bad.
NTLA EDIT IP GILD INPAP CRSP

15
EDIT / Editas Medicine, Inc. 8-K (Current Report)

2018-06-19 sec.gov
edit_Current_Folio_8K
EDIT

81
Gilead Oncology CAR T-Cell Therapies Outlook Compelling

2018-06-18 seekingalpha
If cell therapies are curative, new business models will become more cyclical. Harvoni and Sovaldi cure rates exceeding 90% show Gilead understands this new paradigm.
VYGR BOLD NTLA ATRA EDIT GILD CRSP ABEO ABEOW ONCE

14
Is Editas Medicine (EDIT) Stock Outpacing Its Medical Peers This Year?

2018-06-18 zacks
Investors focused on the Medical space have likely heard of Editas Medicine (EDIT - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
EDIT

26
Think Twice Before Divesting In Crispr Amid Cancer Concerns

2018-06-15 seekingalpha
Two publications released Monday morning suggest CRISPR-Cas9 editing may lead to systematic propagation of cancer-prone cells.
NTLA EDIT CRSP

481
Your Daily Pharma Scoop: Tetraphase Positive Data, MediWound In Phase 3, Allergan Moves Up

2018-06-13 seekingalpha
Tetraphase Pharma (TTPH) has a PDUFA on August 28 for its lead drug candidate ERAVACYCLINE in one indication - cIAI - complicated intra-abdominal infections. This PDUFA is based on an NDA filed on Feb 27 - the 6-month duration comes from a Fast Track designation; they also have a Qualified Infectious Disease Product (‘QIDP) for the drug candidate.
NTLA MKGAF OPK RCUS CORV ENL AQXP CUR EDIT ALXN AGN ADXS PFNX GTBP AMGN VTGN CRSP MDWD LLY SNY VICL LIVN MKGAY LIVN ENDP

14
Editas Medicine to Participate in The JMP Securities Life Sciences Conference

2018-06-13 globenewswire
CAMBRIDGE, Mass., June 13, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will participate in a panel and host investor meetings at the JMP Securities Life Sciences Conference in New York on Wednesday, June 20, 2018. Details of the panel are as follows:
EDIT

25
Crispr Therapeutics Down On Cancer Concerns - Unjustified Market Reaction?

2018-06-12 seekingalpha
Two reports in Nature and one interpretation of a STAT News report have taken the three CRISPR stocks down.
NTLA EDIT CRSP

37
Crispr Therapeutics: Beware Of Articles Minimizing The Clinical Hold Risk

2018-06-11 seekingalpha
Articles published last week appear to be examples of confirmation bias showing too little regard for the potential risk factors associated with CRISRP editing.
NTLA VRTX EDIT BLUE CRSP BLUE

23
EDIT / Editas Medicine, Inc. 424B7 (Prospectus)

2018-06-08 sec.gov
CALCULATION OF REGISTRATION FEE
EDIT

26
EDIT / Editas Medicine, Inc. 8-K (Current Report)

2018-06-08 sec.gov
UNITED STATES SECURIT
EDIT

19
EDIT / Editas Medicine, Inc. 8-K (Current Report)

2018-06-08 sec.gov
edit_Current Folio_BroadSRA_8K
EDIT

165
Crispr On Hold While Sangamo Accelerates

2018-06-04 seekingalpha
The gene editing group relying on Crispr was negatively impacted by the FDA hold on CTX001 last week.
NTLA AVXS CRSP ABEO ONCE RGNX VYGR BOLD EDIT CELG NVS BLUE ABEOW PFE

61
A Closer Look: Magenta Therapeutics IPO

2018-06-04 seekingalpha
Magenta has one phase 2 asset and several preclinical assets being developed to provide safer and more effective bone marrow transplants.
SAGE NTLA EDIT CTMX GBT

28
Should You Buy the Dip in CRISPR Therapeutics?

2018-05-31 zacks
We recently documented the potential of Genome Editing technology to revolutionize the treatment of many serious diseases and three companies who are positioned to use a specific method of gene therapy called CIRSPR Cas9 to repair genetic diseases - CRISPR Therapeutics (CRSP - Free Report) , Intellia Therapeutics (NTLA - Free Report) and Editas Medicine (EDIT - Free Report) .
NTLA VRTX ELY EDIT CRSP

Related Articles

CASC: Cascadian Therapeutics Analysis and Research Report

7h - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

8h - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

Silicon Investor Message Boards

This table lists all message boards related to EDIT / Editas Medicine, Inc. on message board site Silicon Investor.

The Epic American Credit and Bond Bubble Laboratory Credit Card Deals
Expeditors Intu0027l (EXPD) Credit Boom and Bust
Welcom to IEarnedItu0027s Domain IEarnedItu0027s Homestead
Forbes-Meditech, FMI,V Iron condors and other credit spreads
Option Spreads, Credit my Debit Real estate and credit file cabinet - please read rules befo
CUSIP: 28106W103